# Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure

> **NCT00219180** · PHASE3 · COMPLETED · sponsor: **Novartis** · enrollment: 1797 (actual)

## Conditions studied

- Hypertension

## Interventions

- **DRUG:** aliskiren

## Key facts

- **NCT ID:** NCT00219180
- **Lead sponsor:** Novartis
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-06
- **Primary completion:** 2006-09
- **Final completion:** 2006-09
- **Target enrollment:** 1797 (ACTUAL)
- **Last updated:** 2017-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00219180

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00219180, "Clinical Study to Evaluate Efficacy and Safety of Aliskiren (150mg & 300mg) Administered Alone and in Combo With Valsartan (160mg and 320mg) in Patients With High Blood Pressure". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00219180. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*